Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 3/20 | 0.44 |
| ▸ | BCR | P11274 | 3/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.43 |
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.43 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420990 | 0.85 | AVPR2 (0.44) | SLC6A7ALDH1A1RAB9AHPGDNAAA | |
| SCHEMBL4422938 | 0.79 | NPC1 (0.53) | ALDH1A1RAB9AHPGDNAAA | |
| SCHEMBL4425355 | 0.78 | NAAA (0.68) | EPHX1CYP2D6EPHX2ALDH1A1RAB9A | |
| SCHEMBL4323354 | 0.78 | CNR2 (0.44) | SLC6A7CNR2EPHX1CYP2D6EPHX2 | |
| SCHEMBL4766522 | 0.76 | NAMPT (0.43) | CNR2CYP2D6ALDH1A1RAB9ACYP2C9 | |
| SCHEMBL933590 | 0.74 | CYP1A2 (0.47) | SLC6A7CNR2CYP2D6DPP4ALDH1A1 | |
| SCHEMBL4424785 | 0.73 | NISCH (0.49) | — | |
| SCHEMBL4789732 | 0.72 | TGFBR1 (0.61) | CNR2CYP2D6TGFBR1ALDH1A1 | |
| SCHEMBL28175120 | 0.71 | HRH3 (0.61) | CNR2CYP2D6CHRNA7TGFBR1ALDH1A1 | |
| SCHEMBL27613086 | 0.70 | CYP1A2 (0.44) | SLC6A7CNR2CYP2D6DPP4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572678-A4 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | ELAN PHARM INC (US) | 2008-05-07 | — | — | EP | claimed |
| US-7183281-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | claimed |
| US-7074783-B2 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-11 | — | — | US | claimed |
| EP-1572678-A2 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | Elan Pharmaceuticals, Inc. (US) | 2005-09-14 | — | — | EP | claimed |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | claimed |
| US-20040138208-A1 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | claimed |
| WO-2004056319-A2 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS INC. (US) | 2004-07-08 | — | — | WO | claimed |
| US-7635775-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| EP-1572678-A4 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | ELAN PHARM INC (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20070161633-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7183281-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20060293332-A1 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2006-12-28 | — | — | US | disclosed |
| US-7074783-B2 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-20050038099-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
| EP-1501807-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | Elan Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004098590-A1 | 4-BROMO-5- (2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (1-(AMINOCARBONYL) ETH-1-YL) AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20040138208-A1 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004056319-A2 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2003093245-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293332-A1 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | BDKRB2, BDKRB1, PDXK | SLC6A7 1891/4885CNR2 216/4885EPHX1 738/4885 |
| US-20050038099-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | SLC6A7 2178/4885CNR2 187/4885EPHX1 1078/4885 |
| US-20070161633-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, HRH2 | SLC6A7 3591/4885CNR2 17/4885EPHX1 428/4885 |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | BDKRB2, BDKRB1, PDXK | SLC6A7 1979/4885CNR2 159/4885EPHX1 560/4885 |
| US-20040138208-A1 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | BDKRB1, BDKRB2, HRH2 | SLC6A7 2358/4885CNR2 55/4885EPHX1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.